166 related articles for article (PubMed ID: 38497886)
41. Mast Cell-related Prognosis Signature Characterizes Immune Landscape and Predicts Prognosis of Ovarian Cancer.
Li Q; Guan T; Mao J; King BP; Johnson K; Mayberry TG; Cowan BC; Wakefield MR; Fang Y; Zhao Q
Anticancer Res; 2024 Jul; 44(7):2775-2786. PubMed ID: 38925849
[TBL] [Abstract][Full Text] [Related]
42. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
You Y; Yang Q
BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
[TBL] [Abstract][Full Text] [Related]
43. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
44. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
[TBL] [Abstract][Full Text] [Related]
45. Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
Zhu S; Zhao Q; Fan Y; Tang C
BMC Urol; 2023 Dec; 23(1):199. PubMed ID: 38049825
[TBL] [Abstract][Full Text] [Related]
46. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
47. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
48. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
49. Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data.
Wang X; Jiang S; Zhou X; Wang X; Li L; Tang J
Oncol Res; 2023; 31(5):697-714. PubMed ID: 37547756
[TBL] [Abstract][Full Text] [Related]
50. A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer.
Zhu L; Lin Z; Wang K; Gu J; Chen X; Chen R; Wang L; Cheng X
Front Endocrinol (Lausanne); 2024; 15():1372413. PubMed ID: 38529390
[TBL] [Abstract][Full Text] [Related]
51. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
52. Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients.
Gao J; Huo S; Zhang Y; Zhao Z; Pan H; Liu X
Cancer Med; 2023 Jan; 12(1):913-929. PubMed ID: 35621244
[TBL] [Abstract][Full Text] [Related]
53. Identification of two molecular subtypes of dysregulated immune lncRNAs in ovarian cancer.
Liu X; Gao J; Wang J; Chu J; You J; Jin Z
Exp Biol Med (Maywood); 2021 Mar; 246(5):547-559. PubMed ID: 33203236
[TBL] [Abstract][Full Text] [Related]
54. Prognosis and therapy in thyroid cancer by gene signatures related to natural killer cells.
Jin Z; Han Y; Zhang J; Liu Z; Li R; Liu Z
J Gene Med; 2024 Jan; 26(1):e3657. PubMed ID: 38282150
[TBL] [Abstract][Full Text] [Related]
55. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
[TBL] [Abstract][Full Text] [Related]
56. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
57. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
58. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
59. Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer.
Ding B; Yan W; Shen S; Meng D; Chen X; Wang S; Shen Y
Cancer Control; 2023; 30():10732748231168756. PubMed ID: 37078136
[TBL] [Abstract][Full Text] [Related]
60. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
